Furthermore, CRP targets to the p38/MAPK pathway causing lytic bone lesions (27) and activates the PI3K/AKT/mTOR and the ERK/NF-κB pathway thereby inhibiting tumor cell apoptosis via the Fcγ receptor II in multiple myeloma (22). This evidence concerns the gene CRP and neoplasm.